All In Biotech

Drug Trial Radar · NCT02485899

An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

Last checked: Nov 20, 2026Latest source record: Aug 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

23

Actual

Start

Feb 2015

Primary completion

Dec 10, 2020

Study completion Dec 10, 2020

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Jun 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase 1/2 study (190-201) evaluated the efficacy and safety of a 300 mg dose of BMN 190 administered every other week (qow) to patients with CLN2. The dose and regimen for this study (190-202) are based on the results of the 190-201 study. The rationale for this phase 2 extension study is to provide patients who complete the 190-201 study with the option to continue BMN 190 treatment. The 190-202 study is an open label extension protocol to assess long-term safety and efficacy.

Conditions

  • Jansky-Bielschowsky Disease
  • Batten Disease
  • Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
  • CLN2 Disease
  • CLN2 Disorder

Interventions

  • BMN 190Biological

    300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks

  • Intracerebroventricular (ICV) access deviceDevice

    Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Probability of Unreversed 2-point Decline in Motor-language (ML) Score or Score of 0Time frame: Up to Week 289
  2. Probability of Unreversed Motor-language (ML) Score of Zero.Time frame: Up to Week 289

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Children's Hospital Bambino Gesù,IRCCS

    Rome, Piazza, Italy

  • Great Ormond Street Childrens Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.